US Stock of the Day | Kabutaro & Friends

On August 20, 2026, the most talked-about US stock online is Moderna<MRNA>.
Background: On August 19, Moderna announced that its personalized mRNA cancer vaccine Intismeran (mRNA-4157), developed with Merck, met its goals in a Phase 3 trial, reducing the risk of melanoma recurrence and preventing tumor spread when combined with Merck's immunotherapy Keytruda. It marked the first successful late-stage trial for any mRNA-based cancer vaccine, and shares surged as much as nearly 177% intraday on August 19, touching around $142, with the close ranking among the stock's largest single-day gains ever. The same day also brought news that the FDA had approved Moderna's flu vaccine mFLUSIVA for adults 50 and older, adding to the catalysts. On August 20, shares fell roughly 10 to 13% in pre-market trading as profit-taking set in. Several analysts, including Bank of America, Morgan Stanley, and UBS, sharply raised their price targets following the news.